Why the study?
Does antipsychotic polypharmacy improve efficacy, tolerability, and cost-effectiveness in patients with psychotic disorders?
Population
Patients with psychotic disorders, including those with psychotic symptoms refractory to clozapine
Design
Systematic_review
Authors
Loading...
Clinicians should restrict antipsychotic polypharmacy to clozapine-refractory cases; systematic review confirms harms outweigh modest efficacy.
Does antipsychotic polypharmacy improve efficacy, tolerability, and cost-effectiveness in patients with psychotic disorders?
Antipsychotic polypharmacy lacks strong evidence for efficacy and is associated with serious adverse effects and increased costs, suggesting it should be limited to clozapine-refractory psychosis.
Bennekom et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: